Health
Therapy
Cancer Prevention

Heron Therapeutics

$18.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.45 (2.54%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell HRTX and other stocks, options, ETFs, and crypto commission-free!

About

Heron Therapeutics, Inc. Common Stock, also called Heron Therapeutics, is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. Read More The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.

Employees
198
Headquarters
San Diego, California
Founded
1983
Market Cap
1.43B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.10M
High Today
$18.31
Low Today
$17.82
Open Price
$17.82
Volume
345.38K
52 Week High
$42.90
52 Week Low
$16.20

Collections

Health
Therapy
Cancer Prevention
Pharmaceutical
Biotechnology
Medical
Technology

News

Yahoo FinanceMay 9

Heron Therapeutics Reports Q1 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

221
PR NewswireMay 8

Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, at 11:35 a.m. PDT at the Encore Hotel in L...

237
Yahoo FinanceMay 8

When Will Heron Therapeutics, Inc. (NASDAQ:HRTX) Breakeven?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Heron Therapeutics, Inc.'s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. On 31 December 2018, the US$1.3b market-cap posted a loss of -US$178.8m for its most recent financial year. As path to profitability is the topic on HRTX’s investors mind, I’ve decided to gauge market sentiment. In this article, ...

189

Earnings

-$1.09
-$0.88
-$0.66
-$0.45
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.